You are here

STTR Phase I: Development of an Intranasal Vaccine for COVID-19

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 2032325
Agency Tracking Number: 2032325
Amount: $256,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: PT
Solicitation Number: N/A
Solicitation Year: 2020
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-10-01
Award End Date (Contract End Date): 2021-09-30
Small Business Information
United States
DUNS: 081331216
HUBZone Owned: Yes
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 Xingguo Cheng
 (216) 269-6757
Business Contact
 Xingguo Cheng
Phone: (216) 269-6757
Research Institution
 Ohio State University Agricultural Technical Institute
 Renukaradhya Gourapura
1328 Dover Rd
Wooster, OH 44691
United States

 Nonprofit College or University

The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project is development of a novel, safe and effective, non-invasive, vaccine for the COVID-19 pandemic. Currently there is no approved vaccine for SARS-CoV-2, and some candidates are administered intramuscularly. The proposed intranasal vaccine directly interacts with the respiratory tract and may provide improved protection and virus clearance. The proposed vaccine is non-invasive, easy to administer, and may be effective in a single dose, thus impacting future social distancing needs. This Small Business Technology Transfer (STTR) Phase I project will develop an intranasal coronavirus vaccine and determine the most promising formulation, with tasks including: 1) synthesis of novel coronavirus antigens and formulation of intranasal vaccine using liposome nanoparticles, including antigen discovery, liposome nanoparticle formulation, and in vitro characterization; 2) preclinical testing of intranasal coronavirus vaccine in an animal model, including intranasal vaccination, serum antibody analysis, virus challenge and analysis of protection efficacy. The outcome of this Phase I study is to obtain an optimized nanoparticle intranasal vaccine formulation for induction of robust T and B cell responses specific to SARS-CoV-2 S and N protein. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government